Extract

The objective of this trial is to define the minimum effective dose of BF 2.649 between 5 mg, 10 mg, 20 mg or 40 mg versus placebo in reducing the Excessive Daytime Sleepiness of Parkinson's disease patients

Inclusion criteria

• Excessive Daytime Sleepiness ,Parkinson's disease

Links

• ictrp
• nct